ArticleFrontiers in endocrinology2026
Clinical features, comorbidities, and therapeutic outcomes of Cushing syndrome: a retrospective multicenter study from Saudi Arabia.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cushing syndrome (CS) is associated with significant morbidity and mortality, but data from the Middle East, including Saudi Arabia, are limited. This study aimed to characterize the demographics, clinical features, comorbidities, diagnostic findings, treatments, and outcomes in a Saudi Arabian multicenter tertiary-referral cohort. Methods: In this retrospective multicenter study, 146 patients with confirmed CS were included. Demographics, clinical features, laboratory and imaging results, treatments, and outcomes were collected and analyzed according to etiological subtype. Results: Among 146 patients (114 women, 32 men; mean age at last recorded follow-up or data abstraction, 42.2 ± 14.7 years), pituitary CS was the most common etiology (61.0%). The mean diagnostic delay was 7.5 years (median 5 years). Hypertension (62.3%) and dysglycemia (67.1%) were prevalent. Among the 88 patients who underwent bone mineral density assessment, 71.6% had abnormal bone health; this selected-subgroup estimate should not be generalized to the entire cohort. Hypokalemia was frequent in ectopic CS (84.6%). Treatment was etiology-specific: 85.4% of the patients with pituitary CS underwent transsphenoidal surgery (TSS), and 87.9% of patients with adrenal CS who underwent adrenalectomy had a unilateral procedure. Crude mortality was 5.1% (7/138 patients with known vital status), remission was documented in 66.9% (93/139 with recorded outcomes), and recurrence after a documented remission occurred in 12 patients. Conclusion: In this Saudi Arabian multicenter tertiary-referral cohort, CS predominantly affects women and is most frequently attributable to pituitary CS. Diagnostic delay remains prolonged despite advances in diagnosis and management. Descriptive treatment outcomes were broadly consistent with international experience; crude mortality was 5.1% among patients with known vital status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.